Algert Global LLC Purchases 51,810 Shares of Dyne Therapeutics, Inc. $DYN

Key Points

• Algert Global increased its Dyne Therapeutics position by 11.4% in the second quarter, buying 51,810 shares for a total holding of 506,273 shares valued at approximately $11.2 million. Institutional investors collectively own 96.68% of the company.
• Analyst sentiment is broadly positive, with Dyne receiving a consensus “Moderate Buy” rating and an average price target of $34.42, although ratings range from “Strong Buy” to “Strong Sell.”
• Insiders have been significant sellers, disposing of 4.14 million shares worth about $99.4 million over the past three months; separately, Dyne reported a quarterly loss of $1.08 per share, missing the $0.75 consensus estimate.

Algert Global LLC raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 11.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506,273 shares of the company's stock after buying an additional 51,810 shares during the quarter. Algert Global LLC owned about 0.27% of Dyne Therapeutics worth $11,244,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. grew its stake in shares of Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock worth $343,085,000 after buying an additional 14,727,667 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Dyne Therapeutics during the 2nd quarter valued at about $275,500,000. Vanguard Group Inc. lifted its holdings in shares of Dyne Therapeutics by 14.9% in the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company's stock valued at $219,376,000 after acquiring an additional 1,455,151 shares during the last quarter. State Street Corp lifted its holdings in shares of Dyne Therapeutics by 27.0% in the 4th quarter. State Street Corp now owns 6,692,745 shares of the company's stock valued at $130,910,000 after acquiring an additional 1,423,828 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its position in Dyne Therapeutics by 45.5% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company's stock worth $101,164,000 after acquiring an additional 1,618,000 shares in the last quarter. Institutional investors own 96.68% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on DYN. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Monday, August 17th. Wall Street Zen lowered Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Evercore set a $33.00 target price on Dyne Therapeutics in a report on Friday, May 15th. Sanford C. Bernstein boosted their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a "market perform" rating in a research report on Wednesday, May 13th. Finally, Cantor Fitzgerald started coverage on Dyne Therapeutics in a report on Thursday, July 23rd. They set an "overweight" rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Dyne Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $34.42.

Insiders Place Their Bets

In related news, CFO Erick Lucera sold 2,362 shares of the firm's stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the transaction, the chief financial officer owned 121,563 shares of the company's stock, valued at $2,476,238.31. This trade represents a 1.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jason P. Rhodes sold 2,160,516 shares of Dyne Therapeutics stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the sale, the director owned 428,946 shares of the company's stock, valued at $10,723,650. The trade was a 83.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,139,196 shares of company stock valued at $99,449,852 over the last three months. Insiders own 9.46% of the company's stock.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $26.34 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. Dyne Therapeutics, Inc. has a 1-year low of $11.92 and a 1-year high of $27.31. The firm has a market capitalization of $4.92 billion, a P/E ratio of -7.91 and a beta of 1.07. The company's 50-day moving average is $23.99 and its 200 day moving average is $19.89.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). Research analysts forecast that Dyne Therapeutics, Inc. will post -3.47 EPS for the current year.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source